标题
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
作者
关键词
-
出版物
Journal of Translational Medicine
Volume 10, Issue 1, Pages 146
出版商
Springer Nature
发表日期
2012-07-12
DOI
10.1186/1479-5876-10-146
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
- (2011) R. R. Huang et al. CLINICAL CANCER RESEARCH
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation
- (2010) Kirsten M.L. Hertoghs et al. JOURNAL OF CLINICAL INVESTIGATION
- Imaging of CTLA4 Blockade-Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab
- (2010) A. Ribas et al. JOURNAL OF NUCLEAR MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
- (2010) Begoña Comin-Anduix et al. PLoS One
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
- (2009) A. Ribas et al. CLINICAL CANCER RESEARCH
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- CTLA-4 co-receptor impacts on the function of Treg and CD8+T-cell subsets
- (2009) Christopher E. Rudd EUROPEAN JOURNAL OF IMMUNOLOGY
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
- (2009) Erika von Euw et al. Journal of Translational Medicine
- Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
- (2009) Hong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- fdrtool: a versatile R package for estimating local and tail area-based false discovery rates
- (2008) K. Strimmer BIOINFORMATICS
- Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
- (2008) A. Ribas et al. CLINICAL CANCER RESEARCH
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
- (2008) Lawrence Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells
- (2008) Aurelie T Bauquet et al. NATURE IMMUNOLOGY
- CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell Death
- (2008) Helga Schneider et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation